Jardiance Lowers Hospitalization Risk in Some Patients
Jardiance lowered risk of hospitalization from acute kidney injury but increased risk of hospitalized from diabetic ketoacidosis compared with a DPP4 inhibitor in one interim analysis.
Teva Recalls One Lot of Topotecan
While the risk of exposure is low, it presents a severe hazard.
FDA Approves Safety Updates to Synjardy Label
The label for the type 2 diabetes treatment has been updated to include the risk of ketoacidosis and damage to the kidney.
Bayer Introduces Updated Packaging for Stivarga
The anticancer therapy is now available in 21-count bottles to help accommodate dispensing.
Reducing Cardiac Toxicity During Cancer Treatment
Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.
ASCO Abstracts Focus on Adverse Events of Checkpoint Inhibitors
Immune-related AEs can occur one to two years after treatment, are more common in combination treatments, and can be difficult to manage.
2 Clarke Drive Cranbury, NJ 08512